Interferon beta-1a belongs to the group of medications known as immunomodulators. Interferon is a substance that is naturally made by our body's cells to fight infections and tumours. Many diseases such as multiple sclerosis and   more »

Glatiramer acetate is used in the treatment of the relapsing-remitting form of multiple sclerosis (MS). This medicine will not cure MS, but may extend the time between relapses. This medicine is available only with your   more »

Interferon beta-1b belongs to a class of medications known as immunomodulators. It is used to reduce the frequency of exacerbations (worsening of symptoms) in people suffering with relapsing-remitting multiple sclerosis. Multiple sclerosis (MS) is caused by   more »

Interferon beta-1a belongs to a group of medications known as immunomodulators. It is a form of a protein that occurs naturally in the body. Interferon beta-1a is used to treat relapsing forms of multiple sclerosis (MS), a chronic and disabling disease that affects the central nervous system (CNS) by destroying the protective covering (myelin   more »

We describe a 41-year-old woman with multiple sclerosis, who presented with redness of the skin; several discoloured areas; along with inflammatory small,   more »

According to the new report entitled Treatment Algorithms in Multiple Sclerosis, neurologists note that Copaxone's better short-term and long-term side-effect/safety profile, together with its lower rate of induction of neutralizing antibodies, are critical reasons for choosing Copaxone   more »

Merck Serono, a division of Merck KGaA, has announced that Rebif® New Formulation (interferon beta-1a) will be available in the UK. In a recent two-year (96 week) Phase IIIb study, 260 patients with relapsing remitting multiple sclerosis treated with the new formulation experienced a near three-fold   more »

Dear Healthcare Professional, Biogen ldec and Elan are writing to inform you of new safety information regarding TYSABRI" (natalizumab). The full Prescribing Information has been revised to add to the   more »

A letter posted to the Food and Drug Administration's Web site says that patients taking Tysabri, which is manufactured at a facility in Research Triangle Park, have developed signs of liver injury as soon as six days after taking their first dose.   more »

The results showed that treatment with COPAXONE® (glatiramer acetate injection) reduced the risk of developing clinically definite MS (CDMS) by 44 percent versus placebo, and   more »

Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and   more »

Q. Where can I call to get more information about Tysabri? The Tysabri Care Program is a registry that supports the safe and effective use of Tysabri. Its goals are to: · To inform people about the risks and benefits of Tysabri prior to treatment   more »

Q. Will my insurance cover the cost of Tysabri? A. According to Biogen Idec Canada, most private insurers are now reimbursing the cost of Tysabri. Generally insurance companies require prior authorization before they will   more »

Q. What is Tysabri (pronounced Tie-SAB-bree) and how does it work? A. Tysabri (whose scientific name is natalizumab, pronounced: nat-tal-IZ-zue-mab) is a laboratory-produced monoclonal antibody. It was formerly called Antegren. It had been approved for   more »

There are 6 US Food and Drug Administration (FDA)-approved DMTs in the United States at this time. These DMTs are IFN beta-1a (intramuscular or subcutaneous), IFN beta-1b, glatiramer acetate, mitoxantrone, and natalizumab. All of   more »